Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Inmune Bio (INMB) Stock Price & Analysis

895 Followers

INMB Stock Chart & Stats

$1.10$0.00(0.00%)
At close: 4:00 PM EST
$1$1.5$2$2.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.09 - $1.15
52-Week Range
$1.06 - $2.60
Previous Close
$1.10
Volume
N/A
Average Volume (3M)
297.74K
Market Cap
$34.05M
Enterprise Value
$39.11M
Total Cash (Recent Filing)
$16.33M
Total Debt (Recent Filing)
$1.21M
Price to Earnings (P/E)
―
Beta
1.63
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
-0.21
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Readiness

Written MHRA alignment and completion of the pre-MAA package reduce uncertainty around the planned UK submission and show progress across key review areas. This regulatory preparation supports a credible path toward potential approval and moves Ebstrocel closer to becoming a commercial product.

Capital-Efficient Commercialization

The Uniphar relationship gives INmune Bio access to distribution and market-entry capabilities without requiring a full country-by-country commercial infrastructure. That outsourced model could make international expansion more capital efficient while supporting named-patient access and future launches.

Low Financial Leverage

Very low leverage limits fixed financial obligations and preserves flexibility while the company advances its pipeline. Compared with more highly indebted development-stage peers, this balance-sheet structure reduces debt-related risk and leaves management more room to allocate capital toward regulatory and clinical priorities.

Bears Say

Pre-Commercial Revenue Profile

INmune Bio has not yet demonstrated a recurring commercial revenue base, while losses remain substantial despite improving from prior years. Until a product is approved and generates sales, the company lacks self-funded operating economics and remains dependent on successful development and commercialization execution.

Persistent Cash Burn

Continued negative operating and free cash flow means the business consumes capital to sustain research and development rather than generating funds internally. Although burn has improved, ongoing deficits can require additional financing and may constrain investment capacity or increase shareholder dilution risk.

Approval And Revenue Timing Uncertainty

The lead asset remains exposed to regulatory review, application validation, possible requests for more information and uncertain U.S. timing. Even with planned submissions, approval and commercialization could be delayed, leaving the company without predictable product revenue for longer than expected.

Inmune Bio News

INMB FAQ

What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.06 and its highest was $2.60 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $34.05M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 111 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Nov 05, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.023.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.21.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 30,959,080 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went down -3.83%.
Which hedge fund is a major shareholder of Inmune Bio?
Hedge funds hold Inmune Bio shares: the largest hedge-fund position in Inmune Bio is 71,887,703 shares, and hedge funds decreased their holdings by 882.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology